Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Certain compounds can boost hair and nail growth.

Minoxidil analogs can be improved for hair growth inhibition by modifying specific parts of their structure.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Onabotulinum toxin A may help treat trichotillomania and promote hair growth.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Some blood thinners can cause hair loss, but switching medications can stop it.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

TLR7-based compounds may help manage chemotherapy-induced hair loss.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.

The new fluoroquinolone effectively fights certain bacteria.

Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.

Pranlukast and mirabegron may work as new diabetes drugs.

Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.

Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

Upadacitinib effectively treats pyoderma gangrenosum.

Thrombospondin-1 is crucial for hair follicle regression and reduced blood vessel growth during the catagen phase.

A new microneedle patch effectively promotes hair regrowth with less frequent dosing.

Minoxidil improved hair growth in a child with a rare genetic disorder.